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NOAC vs warfarin.Atrial ﬁbrillation (AF) is the most common sustained cardiac
arrhythmia. It is estimated that over 35 million individuals are
affected worldwide and only in the US, the prevalence of AF is
expected to rise to between 6 and 12 million in 2050.1 Patients
with AF have a 5-fold increase risk of stroke, which represents
the ﬁrst cause of long-term disability and the third cause of
death in this patient population.2 The incidence of AF
increases exponentially with age, and elderly patients have
a higher percentage of strokes attributed to AF.3 For several
years, oral anticoagulation (OAC) with vitamin K antagonists
(VKAs) has represented the mainstay of treatment for stroke
prevention in patients with AF. However, due to the narrow
therapeutic window and bleeding concerns, VKAs have been
historically underused. Many physicians have then looked at
the advent of the new oral anticoagulants (NOACs) as the
answer to achieve a balance between the risk of thromboem-
bolism and the risk of bleeding in patients with AF. Indeed, as
compared to warfarin, NOACs have been shown to not only
reduce the risk of stroke but also to reduce the rate of major
bleeding, in particular intracranial (IC) bleeding.4 However, the
occurrence of major bleeding with NOACs has not disap-
peared, ranging between 1.6% and 3.11% per year (Fig. 1).
Moreover, although the rate of IC bleeding has been signiﬁ-
cantly reduced with NOACs, some of them are associated with
an increased risk of gastrointestinal bleeding. Other concerns
with OAC include patients with high risk of falls, renal and
liver dysfunctions (who were typically excluded from NOACs
studies), and those requiring dual antiplatelet therapy after
stenting. It is also important to underscore that despite their
more predictable anticoagulant effect and ease of use, the
percentage of permanent treatment discontinuation with
these new drugs in recent pivotal randomized trials remained
high between 21% and 33%, which was similar to the rate of
discontinuation seen with warfarin (Fig. 2). These recognized
limitations of OAC have deﬁned several compelling reasons as
to why device closure of the left atrial appendage (LAA) has
emerged as an attractive and important concept. The rationale
for LAA closure stems from observational studies showing that
in patients with non-valvular AF, the vast majority (>90%) of§ This editorial is pertaining to the article: Percutaneous left atrial a
center experience from India.thrombus is located in the LAA.5 The goal of this technique is
to address the unmet needs of stroke prevention in AF that
persist despite recent advances in OAC therapy. Currently, the
two most commonly used LAA closure devices are the
Watchman device (Boston Scientiﬁc, Plymouth, MN, US) and
the Amplatzer Cardiac Plug (ACP)/Amulet (St. Jude Medical,
Minneapolis, MN, US). In the PROTECT-AF trial, 707 patients
with AF and eligible for OAC treatment were randomly
assigned in a 2-to-1 ratio to receive the Watchman device or
warfarin.6 At 18 months follow-up, the noninferiority margin
for the primary composite end point of stroke, cardiovascular
death, and systemic embolism was met, though adverse
events were more common in the device group, mostly related
to procedural complications. The safety issue with Watchman
implantation was further investigated by the smaller random-
ized PREVAIL trial, which showed a dramatic reduction in
procedural complications, although the prespeciﬁed end-point
for noninferiority against warfarin was not met.7 Recently, 4-
year results of PROTECT-AF demonstrated superiority of theppendage closure in AF using Amplatzer Cardiac Plug: First single
Fig. 2 – Permanent treatment discontinuation in recent
randomized trials NOAC vs warfarin.
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compared to optimal medical treatment with warfarin.8
Based on the results of these two randomized trials, the
Watchman device received approval by the US Food and Drug
Administration in March 2015 as an option for high-risk AF
patients seeking an alternative to warfarin. The ACP has a
large real-world experience over the past 5 years. In an
international multicenter ACP registry, 1047 patients were
included and followed for a mean of 13 months.9 The main
indications for LAA closure were a history of previous major
bleeding and patients at high-bleeding risk. This study showed
a high procedural success rate of 97.3% and periprocedural
major adverse event rates of 4.97%. Annual rates of stroke,
systemic thromboembolism, and major bleeding were 0.9%,
2.3%, and 2.1%, respectively. Due to this growing body of
evidence demonstrating efﬁcacy for stroke prevention and
acceptable safety outcomes, LAA closure has progressively
gained worldwide acceptance as a valid alternative to OACs,
mainly in patients who have a contraindication to this
therapy. In this issue, Shetty and colleagues describe the ﬁrst
reported clinical experience of LAA closure in India. Using the
ACP, LAA closure was performed in 10 consecutive patients
with AF over a 3-month period. Indications for LAA closure
were the presence of a high-bleeding risk (based on the HAS-
BLED score), labile INR, or drug incompliance. Procedural
success was achieved in all patients with no procedural
complication and no adverse event during short-term follow-
up. The procedural steps for successful device implantation
are clearly described, underscoring the importance of a careful
and systematic methodology including adequate transseptal
puncture technique, accurate sizing of the landing zone for
device deployment, and checklist assessment of optimal
device position before ﬁnal release. Despite being a single-
center experience with a limited number of patients, these
results are encouraging and should be regarded as a pioneer
clinical experience in India. With one of the largest population
of patients with AF in the world and with issues regarding theavailability of OAC therapy, especially in rural populations, the
clinical need for an alternative therapy such as LAA closure in
India is evident. Although it can be viewed initially as an
expensive therapy, the majority of LAA closure costs are borne
in the ﬁrst year, while costs of OAC continue to increase over
many years.10 Thus, LAA closure may represent an opportu-
nity for savings to healthcare systems in the long term. By
implementing this breakthrough technology in India, Shetty
and colleagues should be commended for paving the way to a
better future for stroke prevention in Indian patients.
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